SAN FRANCISCO, SUZHOU, China, April 30, 2024/PRNewswire/ -- Cinda Biopharmaceuticals (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as oncology, autoimmunity, metabolism, cardiovascular, and ophthalmology, announced today the appointment of Dr. Samuel Zhang (Samuel Zhang) as Global Chief Commercial Officer (CBO). Dr. Zhang will be responsible for the strategic planning and business development of Cinda Biotech's global business and will report to Dr. Yu Dechao, the founder, chairman and CEO of the company.
Dr. Zhang has more than 20 years of industry experience in drug research, development, commercialization, and business cooperation. He has proactively identified emerging industry trends and prospects, and has repeatedly promoted major R&D decisions for large pharmaceutical companies and small biotechnology companies. It also designs science-based market development strategies to solve a large number of unmet medical needs, so that the company can achieve commercial value and facilitate large-scale strategic transactions in a competitive market.
Prior to joining Cinda Biotech, Dr. Zhang was the chief commercial officer of Genxi Biotech and NeoImmune Tech. Dr. Zhang led the $1.2 billion acquisition cooperation between Genxi Biotech and AstraZeneca. This is the first time that an innovative Chinese pharmaceutical company has been acquired by a multinational pharmaceutical company. He has also held various management positions at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus.
Dr. Zhang has a doctorate degree in molecular biology from Columbia University, an MBA from the Wharton School of the University of Pennsylvania, and a bachelor's degree in biology from Peking University.
Dr. Yu Dechao, founder, chairman and CEO of Cinda Biotech, said:“I am very happy that Dr. Zhang Suhua joined Cinda Biotech as Chief Commercial Officer. Dr. Zhang has extensive experience and excellent leadership skills in the field of business development. We believe Dr. Zhang's addition will enhance Cinda Biotech's international strategic planning and business development capabilities, and further accelerate the pace of Cinda's globalization.”
Dr. Zhang Suhua said:“Since its establishment 12 years ago, Cinda Biotech has achieved great success. It is a company with a strong focus on development strategies and international cooperation. I am very happy to join Cinda Biotech at this time to help the company build on a solid foundation of development and partner with more outstanding companies to develop breakthrough medicines to benefit patients in need around the world.”
About Cinda Biotech
The mission and goal of Cinda Biotech is to develop high-quality biopharmaceuticals that ordinary people can afford to use. Founded in 2011, Cinda Biotech is committed to developing, producing and selling innovative drugs for major diseases such as oncology, autoimmunity, metabolism, and ophthalmology, so that our work can benefit more lives. The company has been approved for listing 10 products. They are cindilizumab injections (dabershu), bevacizumab injection (dayoutong)), adalimumab injection (sulisin), rituximab injection (dabervac), pemitinib tablets (dabartan), orebatinib tablets (Nelik), remocizumab injection (Shiranzane2), ceptinib capsules (Ruitul2), igiorencet injection (Focusol) and tolecizumab injections (Cimpiroc). Currently, there are also 3 varieties in the NMPA review. 5 new drug molecules have entered phase III or key clinical research, and 18 new drug types have entered clinical research.
The company has reached more than 30 strategic partnerships with international partners such as Eli Lilly, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center. While continuously developing innovative drugs and seeking its own development, Cinda Biotech adheres to the people-centered development philosophy of economic construction. Over the years, we have always been scientific and kind, adhering to the “patient-centered” approach, caring for patients and their families, and actively fulfilling social responsibilities. The company has successively initiated and participated in a number of drug charity aid projects, so that more and more patients can benefit from advances in life science and can buy and use high-quality biopharmaceuticals. As of October 2023, the Cinda Biotech Patient Assistance Program has benefited more than 170,000 ordinary patients, with a total drug donation value of RMB 3.4 billion. Cinda Biotech hopes to work with everyone to raise the level of development of China's biopharmaceutical industry to meet people's accessibility to medicine and people's pursuit of a better life and health.
For more information, please visit the company's website: or the company's LinkedIn account.
Declarations:1. Cinda Biotech does not recommend the use of unapproved drugs/indications. |
2. Remocizumab injection (Shiranze) and ceptinib capsules (Ruituo) are developed by Eli Lilly |
Forward-looking statements
The information published in this press release may include certain forward-looking statements. These statements are inherently risky and uncertain. When using “anticipate”, “believe”, “anticipate”, “expect”, “intention” and other similar terms, the purpose of any statement relating to the Company is to indicate that it is a forward-looking statement. The Company is under no obligation to update these predictive statements on an ongoing basis.
These forward-looking statements are based on the Company's management's existing views, assumptions, expectations, estimates, predictions and understandings of future affairs at the time the statements are made. These statements are not a guarantee of future development and are affected by risks, uncertainties and other factors. Some are beyond the Company's control and are difficult to predict. As a result, actual results may differ significantly from the information contained in forward-looking statements due to future changes and developments in our business, competitive environment, and political, economic, legal and social conditions.
The Company, its directors and employee agents are not responsible for (a) any obligation to correct or update the forward-looking statements contained on this website; and (b) any liability arising from the failure or inaccuracy of any forward-looking statements.